View Older Stories View More Recent Stories

Nov 13, 2025 07:00AM Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
Oct 31, 2025 07:00AM Adagene doses first patient in phase 2 colorectal cancer study
Oct 31, 2025 07:00AM Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorec
Sep 16, 2025 08:00AM Adagene expands Exelixis partnership for third masked ADC development
Sep 16, 2025 08:00AM Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
Sep 5, 2025 09:55AM Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China
Sep 3, 2025 09:05AM Adagene names Axel Hoos as executive advisor
Sep 3, 2025 09:05AM Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor
Aug 26, 2025 08:05AM Adagene to Participate in Two Investor Conferences in September
Aug 12, 2025 04:05PM Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates
Jul 15, 2025 07:01AM Adagene receives FDA guidance for phase 2 colorectal cancer trial
Jul 15, 2025 07:00AM Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA
Jul 8, 2025 07:01AM Adagene (ADAG) partners with ConjugateBio for antibody drug conjugate development
Jul 8, 2025 07:00AM Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate
Jul 1, 2025 07:02AM Adagene (ADAG) announces up to $25 million strategic investment from Sanofi (SNY)
Jul 1, 2025 07:00AM Adagene announces up to $25 million strategic investment from Sanofi
May 27, 2025 07:30AM Adagene to Present at Jefferies Global Healthcare Conference 2025
May 22, 2025 05:08PM Adagene Inc. (ADAG) updates data from Phase 1b/2 study of Muzastotug
May 22, 2025 05:05PM Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annu
Apr 28, 2025 08:00AM Adagene Appoints John Maraganore, Ph.D. as Executive Advisor
Apr 23, 2025 10:05AM Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 7, 2025 08:00AM Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum
Mar 24, 2025 08:00AM Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update
Mar 13, 2025 08:00AM Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit
Mar 6, 2025 08:00AM Adagene to Present at Leerink’s Global Healthcare Conference 2025
Feb 27, 2025 08:00AM Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer
Jan 27, 2025 07:01AM Adagene Inc. (ADAG) Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA
Jan 27, 2025 07:00AM Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
Jan 27, 2025 07:00AM Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
Jan 21, 2025 05:00PM Adagene Inc. (ADAG) to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA
Jan 21, 2025 05:00PM Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
Jan 14, 2025 08:00AM Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025
Nov 7, 2024 10:01AM Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Mono
Oct 9, 2024 06:00AM Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Sep 16, 2024 03:01AM Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metas
Aug 29, 2024 07:00AM Adagene to Participate in Investor Conferences in September
Jul 25, 2024 04:05PM Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update
Jul 12, 2024 07:00AM Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congre
May 22, 2024 04:45PM Adagene to Present at Investor Conferences in June
Mar 29, 2024 09:00AM Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
Mar 7, 2024 04:01PM Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
Feb 27, 2024 08:00AM Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
Feb 9, 2024 06:01AM Adagene (ADAG) Announces Progress and Expansion of Clinical Collaboration Program for ADG126 in Combination with KEYTRUDA
Feb 9, 2024 06:00AM Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further
Jan 16, 2024 05:02PM Adagene Inc. (ADAG) Presents Interim Results Reinforcing Best-in-Class Profile of ADG126
Jan 16, 2024 05:01PM Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colo
Jan 4, 2024 05:00AM Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
Nov 3, 2023 12:03PM Adagene Inc. (ADAG) Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody ADG126
Nov 3, 2023 12:00PM Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
Oct 12, 2023 08:00AM Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
View More Recent Stories View Older Stories